157 related articles for article (PubMed ID: 28404691)
1. Exemestane and Its Active Metabolite 17-Hydroexemestane Induce UDP-Glucuronosyltransferase (UGT) 2B17 Expression in Breast Cancer Cells.
Chanawong A; Mackenzie PI; McKinnon RA; Hu DG; Meech R
J Pharmacol Exp Ther; 2017 Jun; 361(3):482-491. PubMed ID: 28404691
[TBL] [Abstract][Full Text] [Related]
2. Impact of UGT2B17 Gene Deletion on the Pharmacokinetics of 17-Hydroexemestane in Healthy Volunteers.
Chen SM; Atchley DH; Murphy MA; Gurley BJ; Kamdem LK
J Clin Pharmacol; 2016 Jul; 56(7):875-84. PubMed ID: 26608382
[TBL] [Abstract][Full Text] [Related]
3. Characterization of 17-dihydroexemestane glucuronidation: potential role of the UGT2B17 deletion in exemestane pharmacogenetics.
Sun D; Chen G; Dellinger RW; Sharma AK; Lazarus P
Pharmacogenet Genomics; 2010 Oct; 20(10):575-85. PubMed ID: 20697310
[TBL] [Abstract][Full Text] [Related]
4. Androgen and Estrogen Receptors in Breast Cancer Coregulate Human UDP-Glucuronosyltransferases 2B15 and 2B17.
Hu DG; Selth LA; Tarulli GA; Meech R; Wijayakumara D; Chanawong A; Russell R; Caldas C; Robinson JL; Carroll JS; Tilley WD; Mackenzie PI; Hickey TE
Cancer Res; 2016 Oct; 76(19):5881-5893. PubMed ID: 27496708
[TBL] [Abstract][Full Text] [Related]
5. Multiple roles for UDP-glucuronosyltransferase (UGT)2B15 and UGT2B17 enzymes in androgen metabolism and prostate cancer evolution.
Gauthier-Landry L; Bélanger A; Barbier O
J Steroid Biochem Mol Biol; 2015 Jan; 145():187-92. PubMed ID: 24861263
[TBL] [Abstract][Full Text] [Related]
6. Role of the UGT2B17 deletion in exemestane pharmacogenetics.
Luo S; Chen G; Truica C; Baird CC; Leitzel K; Lazarus P
Pharmacogenomics J; 2018 Apr; 18(2):295-300. PubMed ID: 28534527
[TBL] [Abstract][Full Text] [Related]
7. Calcitrol (1alpha,25-dihydroxyvitamin D3) inhibits androgen glucuronidation in prostate cancer cells.
Kaeding J; Bélanger J; Caron P; Verreault M; Bélanger A; Barbier O
Mol Cancer Ther; 2008 Feb; 7(2):380-90. PubMed ID: 18281521
[TBL] [Abstract][Full Text] [Related]
8. Androgen glucuronidation: an unexpected target for androgen deprivation therapy, with prognosis and diagnostic implications.
Grosse L; Pâquet S; Caron P; Fazli L; Rennie PS; Bélanger A; Barbier O
Cancer Res; 2013 Dec; 73(23):6963-71. PubMed ID: 24121496
[TBL] [Abstract][Full Text] [Related]
9. A novel polymorphism in a forkhead box A1 (FOXA1) binding site of the human UDP glucuronosyltransferase 2B17 gene modulates promoter activity and is associated with altered levels of circulating androstane-3α,17β-diol glucuronide.
Hu DG; Gardner-Stephen D; Severi G; Gregory PA; Treloar J; Giles GG; English DR; Hopper JL; Tilley WD; Mackenzie PI
Mol Pharmacol; 2010 Oct; 78(4):714-22. PubMed ID: 20628005
[TBL] [Abstract][Full Text] [Related]
10. Differential biological effects of aromatase inhibitors: Apoptosis, autophagy, senescence and modulation of the hormonal status in breast cancer cells.
Augusto TV; Amaral C; Almeida CF; Teixeira N; Correia-da-Silva G
Mol Cell Endocrinol; 2021 Nov; 537():111426. PubMed ID: 34391846
[TBL] [Abstract][Full Text] [Related]
11. Exemestane may be less detrimental than letrozole to bone health in women homozygous for the UGT2B17*2 gene deletion.
Kamdem LK; Xi J; Clark BL; Gregory BJ; Kidwell KM; Storniolo AM; Stearns V; Hayes DF; Gersch CL; Rae JM; Henry NL; Hertz DL
Breast Cancer Res Treat; 2019 Jun; 175(2):297-303. PubMed ID: 30747308
[TBL] [Abstract][Full Text] [Related]
12. Forkhead box protein A1 regulates UDP-glucuronosyltransferase 2B15 gene transcription in LNCaP prostate cancer cells.
Hu DG; Mackenzie PI
Drug Metab Dispos; 2010 Dec; 38(12):2105-9. PubMed ID: 20736324
[TBL] [Abstract][Full Text] [Related]
13. Prognostic impact of genetic variants of CYP19A1 and UGT2B17 in a randomized trial for endocrine-responsive postmenopausal breast cancer.
Johansson H; Aristarco V; Gandini S; Gjerde J; Macis D; Guerrieri-Gonzaga A; Serrano D; Lazzeroni M; Rajasekaran A; Williard CV; Mellgren G; DeCensi A; Bonanni B
Pharmacogenomics J; 2020 Feb; 20(1):19-26. PubMed ID: 30967597
[TBL] [Abstract][Full Text] [Related]
14. The potential clinical benefit of targeting androgen receptor (AR) in estrogen-receptor positive breast cancer cells treated with Exemestane.
Amaral C; Augusto TV; Almada M; Cunha SC; Correia-da-Silva G; Teixeira N
Biochim Biophys Acta Mol Basis Dis; 2020 May; 1866(5):165661. PubMed ID: 31891807
[TBL] [Abstract][Full Text] [Related]
15. Characterization and regulation of UDP-glucuronosyltransferases in steroid target tissues.
Bélanger A; Hum DW; Beaulieu M; Lévesque E; Guillemette C; Tchernof A; Bélanger G; Turgeon D; Dubois S
J Steroid Biochem Mol Biol; 1998 Apr; 65(1-6):301-10. PubMed ID: 9699884
[TBL] [Abstract][Full Text] [Related]
16. Effects of aromatase inhibitors on human osteoblast and osteoblast-like cells: a possible androgenic bone protective effects induced by exemestane.
Miki Y; Suzuki T; Hatori M; Igarashi K; Aisaki KI; Kanno J; Nakamura Y; Uzuki M; Sawai T; Sasano H
Bone; 2007 Apr; 40(4):876-87. PubMed ID: 17254854
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of UDP-glucuronosyltransferase 2B17 (UGT2B17) and dihydrofolate reductase (DHFR) genes deletion and the expression level of NGX6 mRNA in breast cancer.
Eskandari-Nasab E; Hashemi M; Rezaei H; Fazaeli A; Mashhadi MA; Moghaddam SS; Arbabi F; Jahantigh M; Taheri M
Mol Biol Rep; 2012 Dec; 39(12):10531-9. PubMed ID: 23053953
[TBL] [Abstract][Full Text] [Related]
18. Activators of the farnesoid X receptor negatively regulate androgen glucuronidation in human prostate cancer LNCAP cells.
Kaeding J; Bouchaert E; Bélanger J; Caron P; Chouinard S; Verreault M; Larouche O; Pelletier G; Staels B; Bélanger A; Barbier O
Biochem J; 2008 Mar; 410(2):245-53. PubMed ID: 17988216
[TBL] [Abstract][Full Text] [Related]
19. Quantitative characterization of UDP-glucuronosyltransferase 2B17 in human liver and intestine and its role in testosterone first-pass metabolism.
Zhang H; Basit A; Busch D; Yabut K; Bhatt DK; Drozdzik M; Ostrowski M; Li A; Collins C; Oswald S; Prasad B
Biochem Pharmacol; 2018 Oct; 156():32-42. PubMed ID: 30086285
[TBL] [Abstract][Full Text] [Related]
20. Exemestane's 17-hydroxylated metabolite exerts biological effects as an androgen.
Ariazi EA; Leitão A; Oprea TI; Chen B; Louis T; Bertucci AM; Sharma CG; Gill SD; Kim HR; Shupp HA; Pyle JR; Madrack A; Donato AL; Cheng D; Paige JR; Jordan VC
Mol Cancer Ther; 2007 Nov; 6(11):2817-27. PubMed ID: 17989318
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
